- Report
- April 2023
- 164 Pages
Global
From €9159EUR$9,500USD£7,833GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2651EUR$2,750USD£2,267GBP
- Report
- January 2022
- 92 Pages
Global
From €6701EUR$6,950USD£5,731GBP
- Report
- January 2022
- 125 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1446EUR$1,500USD£1,237GBP
- Clinical Trials
- September 2020
- 70 Pages
Global
From €1446EUR$1,500USD£1,237GBP
- Report
- April 2023
- 115 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- October 2021
- 104 Pages
Global
From €4338EUR$4,500USD£3,710GBP
- Report
- April 2021
China
From €2507EUR$2,600USD£2,144GBP
- Report
- December 2022
- 142 Pages
Global
From €4290EUR$4,450USD£3,669GBP
- Report
- September 2022
- 74 Pages
Mexico
From €3230EUR$3,350USD£2,762GBP
- Report
- March 2021
- 48 Pages
Global
€21210EUR$22,000USD£18,140GBP
- Report
- January 2019
- 82 Pages
Global
From €9641EUR$10,000USD£8,245GBP
- Report
- October 2021
- 57 Pages
Global
From €6744EUR$6,995USD£5,768GBP
- Report
- February 2020
- 163 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- June 2020
- 155 Pages
Global
From €3471EUR$3,600USD£2,968GBP
- Clinical Trials
- November 2018
- 1100 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- April 2018
United States
From €7708EUR$7,995USD£6,592GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21210EUR$22,000USD£18,140GBP
- Report
- May 2023
- 78 Pages
Global
From €3500EUR$3,889USD£3,098GBP
Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more